Key patent for Atmofizer’s air purification technology
VANCOUVER, BC, March 9, 2022 /PRNewswire/ – Atmofizer Technologies Inc. (the “Company” Where “atmovisor“) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) today announces that the United States Patent and Trademark Office (the “USPTO“) issued a notice of acceptance for claims related to the Company’s air and water purification technology.
Authorized patent application titled “Ultra-Fine Particle Aggregation, Neutralization and Filtration” (U.S. Patent Application No. 17/471,610) provides broad protection for the application of air and water purification technology. company water.
“This clearance notice provides further validation of our new approach to air and water purification technology and allows Atmofizer to confidently continue to develop its technology.” noted Oliver CentnerCEO of Atmofizer Technologies Inc.
Joel WeissManaging Partner of Weiss & Arons, LLP, and Intellectual Property Advisor to Atmofizer, said, “The granting of the Atmofizer patent validates Atmofizer’s technology solutions to real-world technology problems and signifies the relevance, going forward, of of Atmofizer in the air and water purification markets.
Olivier further states, “This patent is a crucial step in protecting our technology and establishing us as the leaders in purifying the air from even the smallest ultra-fine particles, those that pass through our body’s natural defenses, into our blood. and even our brains. COVID has raised awareness about air quality, the market is growing exponentially and Joel and his team have done a fantastic job of ensuring we protect our technology so we can focus on commercialization .”
A Notice of Allowance is issued after the USPTO determines that a patent should be issued based on an application. A patent of the recently authorized application is pending and is expected to be issued in the near future.
About Atmofizer Technologies Inc.
Atmofizer’s consumer and industrial solutions are based on its patented and patent-pending technology for the agglomeration and neutralization of ultrafine particles. This capability creates a revolutionary and more efficient method of dealing with the wide range of dangerous nanoparticles, viruses and bacteria that are too small to be effectively handled by conventional HEPA filters and ultraviolet lamps. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while reducing operating costs for customers.
Atmofiizing the air refers to the process of using ultrasonic sound waves to agglomerate (cluster) small particles into a larger target which is then irradiated with ultraviolet light to neutralize their harmful properties, making the air you breathe less dangerous to your health. Using units that atmofize the air in tandem with HEPA filters can make HEPA filters more efficient, allow the use of a less powerful filter, and result in a cleaner, longer lasting filter that reduces operating costs. operation and poses fewer health risks. clean or replace.
Atmofizer is the only source of patent-pending, patent-protected technology to atmofize air and applies its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that incorporate Atmofizer technology into their own licensed products. Atmofizer’s owned and licensed product lines include portable, portable and mobile use for personal air handling, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential.
This press release contains “forward-looking information” within the meaning of applicable securities laws. Any statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some instances, forward-looking information may be identified by words or phrases such as “may”, “will”, “expect”, “probable”, “should”, “would”, “expect”, ” anticipates”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative form of these terms, or other similar words, phrases and grammatical variations, or statements that certain events or conditions “can” or “will” happen, or through discussions of strategy. Forward-looking information contained herein includes, but is not limited to, the grant of U.S. Patent Application No. 17/471,610 and the Company’s business and strategic plans.
By its nature, forward-looking information is subject to inherent risks and uncertainties which may be general or specific and which give rise to the possibility that the expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that the assumptions are not correct and that the objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information contained in this press release, including, without limitation: the ability to the Company to comply with all applicable laws and governmental regulations relating to its commercial products; the Company’s ability to protect its intellectual property; impacts on the Company’s business and operations due to the COVID-19 pandemic; the conflict in the east Europe; having only a limited operating history, the Company’s ability to access capital to meet its future financing needs; the Company’s dependence on management and key personnel; competetion; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Other risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be viewed at www.sedar.com. Readers are cautioned to carefully consider these factors, as well as other factors, uncertainties and potential events, and not to place undue reliance on any forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management as of the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, or to explain any material differences between subsequent actual events and such forward-looking information, except as required by applicable law.
SOURCEAtmofizer Technologies Inc.